Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ALEC by emailGet an email when ALEC pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ALEC, unsubscribe in one click. Privacy
📣 What ALEC Says Is Next
Q1 2027 · “The company is targeting an IND submission in Q1 2027 and first-in-human dosing in Australia no later than April 2027.”
Company press release, Aug 6, 2026 · SEC filing
Q1 2027 · “The company is targeting an IND submission in Q1 2027.”
Company press release, May 7, 2026 · SEC filing
in 2027 · “The company is targeting submission of an IND application in 2027.”
Company press release, Feb 25, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ALEC picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALEC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.